What is the dosing for Bismuth (Bismuth subsalicylate) in H. pylori treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Bismuth Dosing for H. pylori Treatment

The recommended dosing for bismuth subsalicylate in H. pylori treatment is 300 mg four times daily (q.i.d.) as part of bismuth quadruple therapy for 14 days. 1

Bismuth Quadruple Therapy Regimen

Bismuth quadruple therapy is the preferred first-line treatment regimen for H. pylori infection when antibiotic susceptibility is unknown, with an eradication rate of approximately 85%. 1 The complete regimen consists of:

  • Bismuth subsalicylate 300 mg four times daily (q.i.d.)
  • Proton pump inhibitor (standard dose) twice daily (b.i.d.)
  • Tetracycline 500 mg four times daily (q.i.d.)
  • Metronidazole 500 mg three times daily (t.i.d.)
  • Duration: 14 days

Evidence Supporting Bismuth Quadruple Therapy

The American Gastroenterological Association recommends bismuth quadruple therapy as first-line treatment for H. pylori infection. 1 This recommendation is supported by research showing superior eradication rates compared to other regimens:

  • Bismuth-based quadruple therapy achieved significantly better eradication rates (82.3%) compared to proton pump inhibitor-based triple regimens (62.7%) in per-protocol analysis. 2
  • Standard bismuth quadruple therapy (rabeprazole, bismuth subsalicylate, metronidazole, tetracycline) showed an eradication rate of 88.3% in intention-to-treat analysis and 92.5% in per-protocol analysis. 3

Alternative Bismuth Dosing Regimens

Some studies have investigated alternative dosing regimens for bismuth:

  • A twice-daily regimen using bismuth subsalicylate 2 caplets twice daily (b.i.d.) for 10 days showed lower effectiveness with an intention-to-treat cure rate of 70%. 4
  • Another study used bismuth subsalicylate 562 mg twice daily (b.i.d.) as part of quadruple therapy with good results (83.8% eradication rate). 3

Clinical Considerations and Caveats

  • Antibiotic Resistance: Increasing resistance to clarithromycin, levofloxacin, and metronidazole is a major cause of treatment failure. 1 Bismuth-based regimens may help overcome resistance issues.
  • Duration of Therapy: 14-day therapy is preferred over shorter durations for optimal eradication rates. 1, 4
  • Side Effects: Bismuth-containing quadruple therapies may have more side effects than triple therapies. Common side effects include darkening of the tongue and stool, nausea, and metallic taste. 3
  • Metronidazole Resistance: The efficacy of bismuth quadruple therapy may be reduced in areas with high metronidazole resistance. 4

Alternative Regimens for Special Populations

For patients with penicillin allergy:

  • Bismuth quadruple therapy with tetracycline instead of amoxicillin is recommended. 1

For patients who have failed previous treatment:

  • If clarithromycin-based therapy fails, bismuth quadruple therapy for 14 days may be used as a second-line treatment option. 1

Confirmation of Eradication

After completing bismuth quadruple therapy, it is recommended to:

  • Wait at least 4 weeks after completing antibiotic therapy before testing for H. pylori eradication. 1
  • Use either the 13C urea breath test or stool antigen test for confirmation of eradication (sensitivity and specificity >90%). 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.